Next Article in Journal
Oncolytic Activities of Host Defense Peptides
Previous Article in Journal
The Impact of the Fusarium Mycotoxin Deoxynivalenol on the Health and Performance of Broiler Chickens
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2011, 12(11), 8013-8026; doi:10.3390/ijms12118013

Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes

Department of Thermobiology, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland
*
Author to whom correspondence should be addressed.
Received: 25 July 2011 / Revised: 2 November 2011 / Accepted: 3 November 2011 / Published: 16 November 2011
(This article belongs to the Section Molecular Toxicology)
View Full-Text   |   Download PDF [321 KB, uploaded 19 June 2014]   |  

Abstract

Diabetes is associated with a mitochondrial dysfunction. Hyperglycaemia is also clearly recognized as the primary culprit in the pathogenesis of cardiac complications. In response to glycation and oxidative stress, cardiac mitochondria undergo cumulative alterations, often leading to heart deterioration. There is a continuous search for innovative treatment strategies for protecting the heart mitochondria from the destructive impact of diabetes. Aminoguanidine derivatives have been successfully used in animal model studies on the treatment of experimental diabetes, as well as the diabetes-driven dysfunctions of peripheral tissues and cells. Considerable attention has been paid particularly to β-resorcylidene aminoguanidine (RAG), often shown as the efficient anti-glycation and anti-oxidant agent in both animal studies and in vitro experiments. The aim of the present study was to test the hypothesis that RAG improves oxidative phosphorylation and electron transport capacity in mitochondria impaired by hyperglycaemia. Diabetes mellitus was induced in Wistar rats by a single intraperitoneal injection of streptozotocin (70 mg/kg body weight). Heart mitochondria were isolated from healthy rats and rats with streptozotocin-diabetes. Mitochondrial respiratory capacity was measured by high resolution respirometry with the OROBOROS Oxygraph-2k according to experimental protocol including respiratory substrates and inhibitors. The results revealed that RAG protects the heart against diabetes-associated injury by improving the mitochondrial bioenergetics, thus suggesting a possible novel pharmacological strategy for cardioprotection. View Full-Text
Keywords: RAG (β-resorcylidene aminoguanidine); mitochondrial respiratory; streptozotocin diabetes; oxygraph Oroboros RAG (β-resorcylidene aminoguanidine); mitochondrial respiratory; streptozotocin diabetes; oxygraph Oroboros
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Labieniec-Watala, M.; Siewiera, K.; Jozwiak, Z. Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes. Int. J. Mol. Sci. 2011, 12, 8013-8026.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top